Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab with Chemotherapy and Bevacizumab plus Radiotherapy in Unresectable or Metastatic Acral Melanoma
ChiCTR2600120280Phase 2Not yet recruiting
- Sponsor
- Southwest Medical University
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in melanoma, sponsored by Southwest Medical University. Primary endpoint: Objective Response Rate (ORR). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR2600120280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120280.